Common Stock

What is common stock?

Common stock is a share of ownership in a business that enables its holder to vote at shareholder meetings and to collect dividends.

Upon payment of all creditors and preferred shareholders, the common stockholders receive their proportionate part of the liquidation profits in the event of corporate dissolution.

When an investor owns the common stock of a company experiencing financial difficulties, this low level of liquidation preference might provide a risk of losing money. However, the majority of the gains flow to common owners when a corporation is profitable.

In many places, the law mandates that each share of common stock be allocated a par value. Technically, par value is the minimum price below which a share of stock cannot be sold. In actuality, par value is typically established at the lowest feasible amount, and in certain places it is not even required by incorporation law. Thus, par value is irrelevant in most circumstances.

In the equity portion of a company’s balance sheet, the dollar amount of common stock recognized by the corporation is listed. The quantity of common stock recorded by a firm is divided between the common stock account and the extra paid-in capital account; the total amount recorded corresponds to the price at which the business sold shares to its investors.

Common Stock

Common Stock Formula

Common shares are shares that may be purchased on the stock market, including those held by institutional investors and business officials (insiders) who own a firm. To calculate common stock, there is a special accounting formula: the number of issued shares minus the number of treasury shares equals the number of outstanding shares of common stock.

Common stock= [Total Equity + Treasury stock]-additional (paid-in) capital-preferred stock-Retained earnings

Common Stock Example

Common shareholders are entitled to specific privileges within the company. According to their share of ownership, they have the opportunity to vote on business affairs and for board members.

Common shareholders also have the right of first refusal to keep their percentage of ownership. For instance, if the firm is attempting to expand its operations by issuing more stock, the one percent owner has the right to purchase extra shares in order to keep his one percent ownership before other investors may acquire it.

The right to earn dividends is one of the several benefits of being a common investor. It is not the right to announce dividends, but the right to receive them when they are declared. Dividends are the distribution to shareholders of retained earnings. It is a return on their investment in the organization. When the board of directors declares dividends, common shareholders have the right to receive a proportion of dividends payable to common stock that corresponds to their ownership stake in the firm.

Features of the Common Shares

  • Stocks Represent Ownership

Common stock represents ownership in a corporation. One share is a fractional ownership stake proportional to the number of outstanding shares. If a corporation issues 100 shares of stock and an investor purchases 10 shares, the investor would control 10 percent of the company. Companies in the real world issue millions, and sometimes billions, of shares. However, each one represents a proportional piece of the company’s stock.

  • Voting Rights

The majority of common stocks have voting rights attached to them. Shareholders elect directors, who then select management accountable for the business’s direction. When a firm is involved in a merger or acquisition, shareholders frequently exercise their voting rights to voice their thoughts on the transactions.

  • Common Share Price

Theoretically, stock prices have no ceiling. In contrast, the value of a company’s stock shares might reach zero, rendering them useless. The dividend payout is one of the appealing features of common stocks. Numerous corporations distribute dividends to investors on a regular basis. This indicates the owner’s portion of earned earnings. In the event that a firm must liquidate or declare bankruptcy, the owners receive whatever is left over after creditors and bondholders are paid.

  • Common Bond Characteristics

The bonds issued by corporations, government agencies, and municipalities reflect loans made by bondholders to a firm or organization. The contract accompanying a bond issuance describes the issuer’s duties to bondholders and the issue’s specific characteristics, such as the interest rate.

  • Transformable and Callable

Some corporate bonds may include a clause allowing the bondholder to exchange the bond for a specific number of shares of the company’s stock. A bond may also be callable, which means that the issuer might require the bondholder to redeem prior to the maturity date.

  • Bond Rates, Maturity and Value

Bond investors do not get dividends in the form of corporate earnings; instead, they receive a coupon rate, which is a set return. Bonds contain an expiration date, also known as the maturity date, which is the day on which the principal is repaid to the investor. The principal is based on the bond’s par, or face value. When estimating future interest rate payments, bond prices are often known beforehand. Nonetheless, bond prices are susceptible to credit risk based on the issuer’s financial health and are influenced by inflation and market interest rates.

Advantages of issuing common stock

  • Performance

Compared to bonds and deposit certificates, the performance of common stocks is superior. However, there is no cap on the investor’s profits from their ownership of common stock. Consequently, common stocks are less costly and more practical alternatives to debt investments.

  • Electoral rights

An investor receives one voting right for each share of common stock held. These voting rights enable investors to participate in the making of company decisions and corporate policy.

In certain instances, investors can elect the board of directors by exercising their voting rights. The more common stock an investor has, the greater influence he will have over a company’s policy.

  • Liquidity

Due to their liquidity characteristics, investors may simply surrender or invest common stocks. Thus, these stocks enable investors to purchase shares and withdraw their whole investment if the firm fails to meet their expectations.

Liquidity gives investors the freedom to use their capital as they see appropriate without difficulty.

  • Limited Legal Liabilities

The responsibility of common shareholders extend beyond the financial investment events that occur within the corporation, and they must be concerned with all legal liabilities.

When a corporation provides increasing returns over time, ordinary shareholders are in a sense passive beneficiaries of a fixed income.

Passive shareholders are not liable in the event that the firm liquidates or encounters legal issues.

Disadvantages

  • Market Risks

The principal risk associated with common stock is market risk. Market risk is the possibility that a firm will underperform over time.

A significant fall in the company’s performance might result in the shareholders consuming the profit and not receiving the dividends they desire.

This is a key criterion to examine since, even when the firm is functioning very well, common shareholders are not the only or first to earn dividends.

  • Uncertainty

Even while ownership of common stock might be considered a fixed-income investment, there is no assurance of dividends. The significant distinction, however, is that the revenue is not guaranteed at the expected time and dependent on the availability of cash in the corporation and how those funds are allocated.

When the corporation begins to distribute dividends, investors and ordinary stockholders are not the only recipients of instant payments.

They get dividends after shareholders and bondholders have received their entire dividend entitlement. Therefore, there is an element of unpredictability and lack of control over the profitability of common stocks.

Frequently Asked Questions

The primary distinction between preferred and common stock is that preferred stock does not grant stockholders voting rights, but common stock does. Preferred shareholders get dividends before regular shareholders because they have preference over a company’s profits.

  1. Preferred stock
  2. Domestic stock
  3. International stocks
  4. Large-cap stocks
  5. Mid-cap stocks
  6. Small-cap stocks
  7. Growth stocks

In the event of a firm liquidation, common stock and preferred stock rank below debt holders as creditors who would get assets. Both common stock and preferred stock represent equity ownership. They gain ownership rights in the corporation, including voting and dividends.

Short-term investors who are unable to hold ordinary stock long enough to overcome share price declines may benefit from investing in preferred stock. This is because preferred stock tends to vary less than common stock, but it also has less potential for long-term gain.

Related Terms

    Read the Latest Market Journal

    China Aviation Oil Sees Strong Recovery with Soaring Jet Fuel Volumes and Expanding Margins

    Published on Mar 24, 2026

    Company Overview China Aviation Oil (CAO) operates as a leading jet fuel supplier and trader, serving as a critical link in China's aviation fuel supply chain. The company's business model centres on jet fuel supply and trading activities, with significant exposure to China's aviation recovery through its associate Shanghai Pudong International Airport. Exceptional Financial Performance CAO delivered impressive results in the second half of 2025, with profit after tax and minority interests (PATMI) exceeding expectations at 55% and 77% of full-year forecasts respectively. The company demonstrated remarkable operational efficiency as gross profit surged 140% year-on-year to US$42.4 million in 2H25, despite revenue declining 1.3% to US$7.9 billion due to lower oil prices. Strong Volume Growth Drives Recovery The company's operational metrics reflect China's robust aviation recovery. Total supply and trading volumes increased 3.4% year-on-year to 12.15 million metric tonnes in 2H25, whilst jet fuel volumes rose significantly by 15.3% to 8.8 million metric tonnes. This growth was underpinned by China's passenger volume recovery, which increased 5.5% to 770 million passengers, with international route passengers surging 21.6% to 79.7 million. Shanghai Pudong International Airport (SPIA) remained a cornerstone of profitability, contributing US$31.9 million in 2H25 profits—44.6% higher year-on-year and representing 52.6% of total PATMI. Key Positives Driving Performance The margin expansion story reflects two critical factors: enhanced negotiating power from higher jet fuel volumes enabling better spread negotiations and improved fixed cost absorption across a larger supply base. Additionally, potential increases in sustainable aviation fuel (SAF) volumes, which carry margins three to five times higher than conventional jet fuel, contributed to profitability improvements. CAO maintains a fortress balance sheet with US$686.9 million in cash and no debt, providing strategic flexibility for dividend increases and investments. Research Outlook Phillip Securities Research maintains a BUY rating with an upgraded target price of S$2.53, previously S$1.50. The research house increased FY26 PATMI forecasts by 32% to account for continued air travel recovery and SPIA's Terminal 3 expansion, which will increase passenger handling capacity by approximately 62.5%. Frequently Asked Questions Q: What drove CAO's strong financial performance in 2H25? A: Jet fuel volumes increased 15.3% year-on-year to 8.8 million metric tonnes, whilst gross profit surged 140% to US$42.4 million due to margin expansion and higher refuelling volumes supported by China's passenger volume recovery. Q: How significant is Shanghai Pudong International Airport to CAO's profitability? A: SPIA contributed US$31.9 million in 2H25 profits, representing 44.6% higher year-on-year growth and accounting for 52.6% of CAO's total PATMI in the period. Q: What is Phillip Securities Research's recommendation and target price? A: Phillip Securities Research maintains a BUY rating with an upgraded target price of S$2.53, increased from the previous S$1.50, representing a 32% increase in FY26 PATMI forecasts. Q: Why did margins expand despite lower oil prices? A: Margin expansion resulted from higher jet fuel volumes enabling better spread negotiation and fixed cost absorption, plus potential increases in sustainable aviation fuel volumes, which carry margins three to five times higher than conventional jet fuel. Q: What is CAO's financial position? A: CAO maintains a strong net cash position of US$686.9 million with no debt, providing flexibility for dividend increases and strategic investments. Cash balance grew US$186.7 million in FY25 due to strong operating cash flows of US$150.5 million. Q: What growth drivers support the upgraded forecasts? A: Growth will arise from higher passenger volumes following SPIA's Terminal 3 expansion, which increases passenger handling capacity by approximately 62.5%, and strategic investments supporting the growing SAF business. Q: How did passenger recovery impact CAO's operations?? A: China's passenger volumes increased 5.5% to 770 million, with international route passengers surging 21.6% to 79.7 million, directly supporting the 15.3% increase in jet fuel volumes. Q: What role does sustainable aviation fuel play in CAO's strategy? A: SAF volumes are expected to grow alongside international travel recovery and carry margins three to five times better than conventional jet fuel, contributing to the company's profitability expansion. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.    Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.

    Centurion Corporation Positioned for Fee Income Growth Despite Mixed Results

    Published on Mar 24, 2026

    Company Overview Centurion Corporation Ltd operates purpose-built worker accommodation (PBWA) and purpose-built student accommodation (PBSA) across Singapore, Malaysia, the UK, and Australia. The company has recently spun off its real estate investment trust, CAREIT, positioning itself to benefit from scalable property management fee income. Financial Performance Highlights Centurion delivered mixed results in 2H25, with revenue exceeding expectations at 105% of full-year forecasts, reaching S$155.2 million. This strong revenue performance was primarily driven by the consolidation of the remaining 55% stake in the 6,290-bed Westlite Mandai facility, which represents 17% of Singapore's bed capacity. However, adjusted profit after tax and minority interests (PATMI) fell short of expectations at 91% of forecasts, impacted by a 33% year-on-year increase in administrative fees due to higher manpower costs. Key Positive Developments Singapore PBWA operations demonstrated robust growth, with 2H25 revenue increasing 24% year-on-year to S$113 million. Beyond the Westlite Mandai consolidation, positive rental revisions contributed to this growth. The newly operational 1,650-bed Westlite Ubi facility, featuring rental rates estimated to be 5-10% higher than existing properties, further supported Singapore revenue expansion. The company's balance sheet has strengthened significantly following CAREIT's spin-off, generating approximately S$473 million in net proceeds. Net debt decreased 38% year-on-year to S$332 million, whilst the net gearing ratio improved substantially to 27% from 46% in FY24. CAREIT's property management fees present a promising revenue stream, with Centurion recognising S$6.5 million in revenue and S$3.2 million in PATMI during 4Q25, achieving a healthy 49% profit margin. Analysts estimate CAREIT's revenue will grow 25% year-on-year in FY26, potentially generating approximately S$16 million in property management fees for Centurion. Challenges Australia PBSA operations faced headwinds, with revenue declining 7.6% year-on-year to S$9 million. Occupancy rates dropped to 93% from 96% in FY24, primarily due to student arrival delays caused by visa requirement changes. However, the Australian government's decision to raise the student visa cap by 9% to 295,000 in August 2025 suggests potential recovery ahead. Investment Outlook Phillip Securities Research maintains a BUY recommendation with an unchanged target price of S$1.81. The firm expects FY26 consolidated adjusted PATMI to decline approximately 14% year-on-year due to increased profit attributable to minority interests from CAREIT's inclusion. Centurion has proposed a special dividend-in-specie distribution of one CAREIT unit for every ten Centurion shares, estimated to yield shareholders approximately 7%. Frequently Asked Questions Q: What drove Centurion's strong revenue performance in 2H25? A: Revenue exceeded expectations primarily due to the consolidation of the remaining 55% stake in the 6,290-bed Westlite Mandai facility and positive rental revisions across the Singapore PBWA portfolio. Q: Why did adjusted PATMI fall below expectations despite strong revenue? A: Adjusted PATMI was impacted by a 33% year-on-year increase in administrative fees, excluding CAREIT IPO fees, primarily due to higher manpower costs. Q: How significant is the CAREIT property management fee income? A: In 4Q25, Centurion recognised S$6.5 million in revenue and S$3.2 million in PATMI from CAREIT property management fees, with a healthy 49% profit margin. This income stream is estimated to grow 25% year-on-year in FY26. Q: What challenges did the Australia PBSA segment face? A: Australia PBSA revenue declined 7.6% year-on-year due to occupancy dropping to 93% from 96%, caused by delays in student arrivals due to visa requirement changes. Q: How has Centurion's balance sheet improved? A: Following CAREIT's spin-off, net debt decreased 38% year-on-year to S$332 million, and the net gearing ratio improved to 27% from 46% in FY24, benefiting from approximately S$473 million in net proceeds. Q: What is Phillip Securities Research's recommendation? A: Phillip Securities Research maintains a BUY recommendation with an unchanged target price of S$1.81, before the dividend-in-specie distribution. Q: What special dividend is Centurion proposing? A: Centurion has proposed a special dividend-in-specie distribution of one CAREIT unit for every ten Centurion shares, estimated to yield shareholders approximately 7%. Q: What is the outlook for Australia PBSA operations? A: The Australian government raised the student visa cap by 9% to 295,000 in August 2025, which is expected to improve Australia PBSA occupancy in FY26 through increased international student demand. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.    Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.

    17LIVE Group Limited Maintains BUY Rating Despite Revenue Decline

    Published on Mar 19, 2026 134 

    Company Overview 17LIVE Group Limited operates as a live-streaming platform company, focusing on interactive entertainment services that connect content creators with audiences through real-time streaming technology. The company generates revenue primarily through its live-streaming platform whilst exploring diversification opportunities to strengthen its market position. Financial Performance and Earnings Turnaround 17LIVE demonstrated resilience in its latest results, with 2H25 earnings showing a significant turnaround despite revenue challenges. Revenue declined 13.4% year-on-year to US$77.6 million, primarily attributed to foreign exchange headwinds and flat growth in the broader live-streaming market. However, the company achieved a notable profit improvement, with PATMI turning positive to US$3.7 million from a loss of US$5.2 million in 2H24. For the full financial year, FY25 revenue reached 91% of forecasts, though PATMI missed expectations with a net loss of US$0.9 million compared to the anticipated US$5.48 million profit forecast. Key Positives Driving Recovery The profit improvement reflects 17LIVE's successful cost optimisation initiatives implemented since 2024. These efforts targeted IT infrastructure, marketing expenses, and organisational efficiency, resulting in operating expenses declining by approximately 2.5% year-on-year to US$32.4 million from US$33.2 million. 17LIVE has enhanced shareholder value through its dividend policy, declaring a final dividend of 0.5 Singapore cents per share for 2H25, bringing the total FY2025 dividend to 2.0 Singapore cents per share. This distribution is supported by the company's robust cash position of US$73.4 million. Operating cash flow turned positive in FY25 to US$4.35 million, compared to negative US$16.7 million in FY24. The company continues executing its share buyback programme launched in 2024, with authority to repurchase up to 10% of issued share capital. As of 2H25, 9 million shares worth US$6.8 million have been repurchased, representing approximately 53% of the authorised limit. Strategic Outlook and Research Recommendation 17LIVE plans to monetise existing assets and diversify revenue streams through initiatives including V-Liver IP, sports collaborations, and short-form drama content, expected to gradually drive user engagement and revenue growth. Phillip Securities Research maintains its BUY rating whilst reducing the target price from S$1.45 to S$1.18, reflecting softer growth assumptions for the live-streaming market and slower monetisation trends. At current levels, 17LIVE trades at an FY26e P/E of 33x. Frequently Asked Questions Q: What was 17LIVE's revenue performance in 2H25? A: Revenue declined 13.4% year-on-year to US$77.6 million, mainly due to foreign exchange headwinds and flat growth in the live-streaming market. Q: How did the company's profitability change in 2H25? A: PATMI turned positive to US$3.7 million from a loss of US$5.2 million in 2H24, driven by ongoing cost-optimisation efforts. Q: What dividend is 17LIVE paying for FY2025? A: The company declared a total dividend of 2.0 Singapore cents per share for FY2025, including a final dividend of 0.5 Singapore cents per share for 2H25. Q: What is Phillip Securities Research's current recommendation? A: They maintain a BUY rating but reduced the target price from S$1.45 to S$1.18, with 17LIVE trading at an FY26e P/E of 33x. Q: How is 17LIVE planning to diversify its revenue streams? A: The company plans to monetise existing assets through initiatives including V-Liver IP, sports collaborations, and short-form drama content. Q: What is the company's cash position? A: 17LIVE maintains a strong cash position of US$73.4 million, with operating cash flow turning positive to US$4.35 million in FY25. Q: How much has the company spent on share buybacks? A: As of 2H25, 9 million shares worth US$6.8 million have been repurchased, representing approximately 53% of the authorised limit under the current mandate. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.    Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.

    Frencken Group Positioned for Semiconductor Recovery

    Published on Mar 19, 2026 300 

    Company Overview Frencken Group Ltd is a Singapore-based precision engineering company that operates across multiple segments including semiconductors, medical devices, industrial automation, and analytical life sciences. The company serves as a key supplier to high-end equipment manufacturers, particularly in the semiconductor industry where it supports advanced lithography machine production. Financial Performance and Outlook Frencken's 2H25 results came in largely within expectations, with revenue and profit after tax and minority interests (PATMI) reaching 103% and 99% of full-year forecasts respectively. The company reported stable 2H25 PATMI of S$19.2 million, representing a modest 1% year-on-year increase. This performance was driven by contrasting segment dynamics across the business portfolio. The Positives Industrial automation emerged as a standout performer, with revenue surging 76% year-on-year to S$26.3 million in 2H25. This impressive growth was primarily attributed to capacity ramp from the company's data storage customer. However, following this order ramp in 2025, industrial automation revenue is expected to decline year-on-year in 1H26. The medical segment also contributed positively, with 2H25 revenue increasing 7% year-on-year to S$65.4 million. This growth was driven by higher demand for X-ray and digital pathology equipment from China, demonstrating the company's ability to capitalise on regional healthcare infrastructure investments. Frencken's financial position strengthened considerably, with net cash spiking 92% year-on-year to S$139.6 million. This improvement was driven by higher inventory sell-through, as inventory days decreased to 105 days in FY25 from 116 days in FY24. The company also increased debt repayment by 32% year-on-year to S$62.5 million in 2H25, reducing total debt to S$22.3 million in FY25 from S$86.6 million in FY24. The Negative The semiconductor segment experienced muted growth, with 4Q25 revenue declining 4% year-on-year to S$112 million. This decrease was attributed to an order recalibration from the company's Netherlands customer. Additionally, the analytical life science segment faced headwinds with a 12% year-on-year decline in revenue due to sluggish demand amid lower research funding in the United States. Investment Recommendation Phillip Securities Research maintains a BUY recommendation with an upgraded target price of S$2.50, increased from the previous S$1.87. The research house believes the semiconductor segment will be Frencken's main growth driver in FY26-27, expecting orders to pick up gradually and ramp in 2H26 when key customers ramp production of the most advanced lithography machines. Frequently Asked Questions Q: What is Phillip Securities Research's recommendation and target price for Frencken Group? A: Phillip Securities Research maintains a BUY recommendation with a target price of S$2.50, upgraded from the previous S$1.87. Q: Which segment performed best in 2H25? A: Industrial automation was the standout performer, with revenue surging 76% year-on-year to S$26.3 million, driven by capacity ramp from the company's data storage customer. Q: Why did the semiconductor segment underperform in 4Q25? A: Semiconductor revenue declined 4% year-on-year to S$112 million due to an order recalibration from the company's Netherlands customer, though this is believed to be transitory. Q: How has Frencken's financial position changed? A: The company's financial position strengthened significantly with net cash spiking 92% year-on-year to S$139.6 million, whilst total debt was reduced to S$22.3 million from S$86.6 million in FY24. Q: What factors affected the analytical life science segment? A: The analytical life science segment experienced a 12% year-on-year decline in revenue due to sluggish demand amid lower research funding in the United States. Q: What is driving the medical segment's growth? A: Medical segment revenue increased 7% year-on-year to S$65.4 million, driven by higher demand for X-ray and digital pathology equipment from China. Q: When does Phillip Securities Research expect the semiconductor recovery to begin? A: The research house expects semiconductor orders to pick up gradually and ramp in 2H26, when key customers ramp production of the most advanced lithography machines. Q: How does Frencken's valuation compare to peers? A: Frencken trades at 20x FY26 price-to-earnings ratio, representing an 18% discount to its peers' average of 24x PE. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.    Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned. This advertisement has not been reviewed by the Monetary Authority of Singapore.

    Ever Glory United Holdings Accelerates Growth Through Strategic Guthrie Acquisition

    Published on Mar 19, 2026 38 

    Company Overview Ever Glory United Holdings Ltd is a prominent mechanical and electrical (M&E) services provider in Singapore. Following its strategic acquisition of Guthrie, the company has positioned itself as one of the largest M&E players in the Singapore market, specialising in complex infrastructure projects including airport facilities, hospitals, and transportation systems. Strong Financial Performance Driven by Strategic Acquisition Ever Glory delivered exceptional results in 2H25, with revenue and adjusted profit after tax and minority interests (PATMI) exceeding expectations at 128% and 122% of forecasts respectively. The company's adjusted PATMI surged 98% year-on-year to S$6.4 million, primarily driven by the consolidation of Guthrie's operations. Additionally, Ever Glory realised a S$5.5 million bargain purchase gain from the Guthrie acquisition, representing the excess of net assets' fair value over the acquisition amount. Record Order Book and Growth Prospects The company's order book experienced remarkable growth, surging 135% year-on-year to S$733 million in 2H25. This substantial increase was fuelled by S$508 million in new contracts secured during 2025, including a significant approximately S$200 million electrical contract for the Alexandra Integrated Hospital redevelopment, alongside maintenance contracts for street lighting and bus depot facility upgrades.  Key Strengths and Market Position Guthrie brings considerable expertise and a proven track record to Ever Glory's operations. At the time of acquisition, Guthrie contributed an order book worth S$312 million, representing approximately 43% of Ever Glory's current total order book. The acquired company has successfully completed major M&E projects, including air-conditioning and mechanical ventilation works for prestigious developments such as Jewel Changi Airport and Funan CapitaLand, as well as lighting services for Changi Airport Runway 3. The enhanced capabilities position Ever Glory to compete for high-value future contracts, including potential projects such as Changi Airport Terminal 5 building and airfield electrical works, LTA MRT tunnel lighting systems, and additional hospital infrastructure contracts. Research Recommendation and Outlook Phillip Securities Research has upgraded Ever Glory to BUY from ACCUMULATE, raising the target price to S$1.05 from S$0.81. The revised valuation is based on 18x FY27e price-to-earnings ratio, representing a 10% discount to its peers' two-year forward PE of 20x. The research fim forecasts revenue and adjusted PATMI to grow at compound annual growth rates of 25% and 36% respectively over the next two years, supported by the record S$733 million order book, which is estimated to provide work for 4-5 years with significant revenue recognition expected towards the latter part of this period. Frequently Asked Questions Q: What was the key driver behind Ever Glory's strong 2H25 performance? A: The primary driver was the consolidation of Guthrie's results following the acquisition. Adjusted PATMI spiked 98% year-on-year to S$6.4 million, excluding the S$5.5 million bargain purchase gain. Q: How significant was the growth in Ever Glory's order book? A: The order book surged 135% year-on-year to S$733 million in 2H25, driven by S$508 million in new contracts secured during 2025, including a major electrical contract worth approximately S$200 million for Alexandra Integrated Hospital redevelopment. Q: What is Guthrie's contribution to Ever Glory's business? A: Guthrie brought an order book of S$312 million at acquisition (43% of Ever Glory's current total) and has a strong track record of completing major M&E projects, including work at Jewel Changi Airport, Funan CapitaLand, and Changi Airport Runway 3 lighting services. Q: What is Phillip Securities Research's current recommendation and target price? A: The research house upgraded Ever Glory to BUY from ACCUMULATE with a higher target price of S$1.05, up from the previous S$0.81. Q: What growth prospects does the research identify for Ever Glory? A: The research forecasts revenue and adjusted PATMI to grow at CAGRs of 25% and 36% respectively over the next two years, with potential to secure high-value contracts such as Changi Airport T5 projects, LTA MRT tunnel lighting, and hospital contracts. Q: How long is the current order book expected to last? A: The S$733 million order book is estimated to provide work for 4-5 years, with significant revenue recognition expected towards the back end of this period. Q: Were there any negative factors identified in the research? A: No significant concerns were identified in the research firm’s analysis. This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst.   Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

    Sea Ltd. Maintains Strong Growth Momentum Across All Segments

    Published on Mar 18, 2026 137 

    Company Overview Sea Ltd. is a leading Southeast Asian technology conglomerate operating three core businesses: Shopee (e-commerce), Monee (digital financial services), and Garena (digital entertainment). The company has established itself as a dominant player in the region's digital economy, leveraging synergies across its platforms to drive user engagement and monetisation. Financial Performance and Outlook Sea Ltd. delivered solid fourth-quarter 2025 results with revenue meeting expectations, though profit after tax and minority interests (PATMI) underperformed due to strategic investments in Shopee's logistics, fulfilment, and user-engagement capabilities. For the full year 2025, revenue and PATMI reached 103% and 89% of estimates respectively. The company demonstrated robust growth with revenue increasing 38% year-on-year whilst PATMI surged 73% year-on-year. Phillip Securities Research maintains its BUY recommendation with an unchanged target price of US$170, derived from a discounted cash flow model using a terminal growth rate of 4.0% and weighted average cost of capital of 7.6%. The firm has rolled forward valuations to FY26e and reduced FY26e PATMI estimates by 1% to account for increased e-commerce investments. Strong Performance Across All Business Segments Shopee continued its impressive growth trajectory with gross merchandise value (GMV) rising 29% year-on-year and gross orders increasing 30% year-on-year. The platform achieved stronger monetisation through advertising, with ad revenue jumping 70% year-on-year driven by a 20% increase in ad-paying sellers and 45% growth in average ad spend per seller. Monthly active buyers grew 15% year-on-year, whilst innovative initiatives like Shopee VIP membership saw subscribers double in just one quarter. Management expects this momentum to persist, guiding for 25% GMV growth in FY26e. Monee demonstrated exceptional expansion with loan principal surging 80% year-on-year to US$9.2 billion. Active credit users increased 40% year-on-year following the transition from a whitelist model to an "all-can-apply" approach. The 90-day non-performing loan ratio remained stable at 1.1%, supported by enhanced underwriting models utilising ecosystem data and artificial intelligence. Monee's adjusted EBITDA exceeded US$1 billion in FY25, now surpassing Shopee as a profit contributor. Garena maintained its position as a durable revenue generator with bookings growing 37% year-on-year to US$2.9 billion. Free Fire achieved two consecutive years of over 30% year-on-year bookings growth, supported by major intellectual property collaborations and newer titles such as EA SPORTS FC Mobile. Frequently Asked Questions Q: What is Phillip Securities Research's recommendation and target price for Sea Ltd.? A: Phillip Securities Research maintains a BUY recommendation with a target price of US$170, unchanged from previous estimates. Q: How did Sea Ltd.'s financial performance compare to expectations in 4Q25? A: Revenue was in line with expectations, whilst PATMI underperformed due to elevated investments in Shopee's logistics, fulfilment, and user engagement. Full-year revenue and PATMI reached 103% and 89% of estimates respectively. Q: What drove Shopee's strong performance in the quarter? A: Shopee's growth was driven by GMV increasing 29% year-on-year, gross orders rising 30% year-on-year, and stronger monetisation through advertising revenue growth of 70% year-on-year. Q: How is Monee's loan portfolio performing in terms of quality? A: The 90-day non-performing loan ratio remains stable at 1.1%, supported by improved underwriting models that leverage ecosystem data and AI technology. Q: What are management's expectations for Shopee's growth in FY26e? A: Management expects momentum to continue and has guided for 25% GMV growth in FY26e, supported by further investments in fulfilment, logistics, and user engagement. Q: Which business segment is the largest profit contributor for Sea Ltd.? A: Monee has become a key profit driver with FY25 adjusted EBITDA exceeding US$1 billion, now surpassing Shopee and ranking second to Garena in terms of profit contribution. Q: How has Garena performed over the past two years? A: Garena has demonstrated durability with Free Fire achieving two consecutive years of over 30% year-on-year bookings growth, whilst FY25 bookings increased 37% year-on-year to US$2.9 billion. This article has been auto-generated using AI tools. It is based on a report by a Phillip Securities Research analyst.   Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

    SATS Upgraded to Buy on Strong Cargo Performance

    Published on Mar 17, 2026 95 

    Company Overview SATS Ltd is a leading aviation services company that provides ground handling and cargo services across multiple regions, including Europe, Asia-Pacific, and the Americas. The company operates cargo facilities and ground handling services for airlines globally, with a significant presence in key aviation hubs. Strong Third Quarter Performance SATS delivered impressive third-quarter results that exceeded analyst expectations, with PATMI reaching 34% of the full-year forecast for the quarter alone. The company's cargo volumes demonstrated robust growth of 7.3% year-on-year to 2.6 million tonnes, driven primarily by strong performance in European and Asia-Pacific markets. Revenue climbed 8% year-on-year to S$1.6 billion in the third quarter, whilst PATMI surged 20.4% to S$84.7 million. This growth was underpinned by the substantial cargo volume increase, with Europe and APAC routes successfully offsetting a 7% decline in the Americas region. Contract Wins Drive Future Growth The company has secured several significant new contracts that are expected to reinforce its cargo strength going forward. These include cargo contracts with China cargo-based operations, Saudia cargo, Azul, and Allegiant Air. The commencement of these new contract wins, combined with additional leasing and capital expenditure initiatives, provides a solid foundation for continued growth. Regional Challenges and Operational Adjustments Despite the overall positive performance, SATS faces some regional challenges, particularly in its US ground handling operations. Lower cargo volumes in this segment have rendered certain stations economically unviable, prompting the company to undertake renegotiations of pricing structures and establish volume thresholds to improve operational efficiency. Upgraded Rating and Target Price Phillip Securities Research has upgraded SATS to a BUY rating with a significantly higher DCF target price of S$4.44, representing an increase from the previous target of S$3.84. This upgrade reflects raised FY26 and FY27 earnings expectations following a 13% increase in FY26 PATMI forecasts. The revision incorporates incremental cargo rate increases amid tightening cargo capacity in the Middle East region and higher projected cargo volumes. New facilities, including the expanded Pathum Thani kitchen and Noida airport cargo facility, are expected to ramp up operations and achieve profitability in the coming quarters. SATS currently trades at 19.5x FY26 price-to-earnings ratio. Frequently Asked Questions Q: What was SATS' cargo volume growth in the third quarter? A: SATS achieved cargo volume growth of 7.3% year-on-year in the third quarter, reaching 2.6 million tonnes. Q: Which regions drove the strong cargo performance? A: Europe and Asia-Pacific routes were the primary drivers of growth, successfully offsetting a 7% decline in the Americas region. Q: What new contracts has SATS secured? A: SATS has won new contracts including China cargo operations, Saudia cargo, Azul, and Allegiant Air services. Q: What is Phillip Securities Research's new recommendation and target price? A: Phillip Securities Research upgraded SATS to a BUY rating with a DCF target price of S$4.44, increased from the previous target of S$3.84. Q: What challenges is SATS facing in its operations? A: The company is experiencing lower cargo volumes in its US ground handling business, making some stations economically unviable and requiring pricing renegotiations and volume threshold establishment. Q: How much did SATS raise its FY26 PATMI forecast? A: SATS raised its FY26 PATMI forecast by 13% due to incremental cargo rate increases and higher projected cargo volumes. Q: What new facilities are expected to contribute to future profitability? A: The expanded Pathum Thani kitchen and Noida airport cargo facility is expected to ramp up operations and become profitable in the coming quarters. Q: At what valuation multiple does SATS currently trade? A: SATS currently trades at 19.5x FY26 price-to-earnings ratio. This article has been auto-generated using PhillipGPT. It is based on a report by a Phillip Securities Research analyst.    Disclaimer These commentaries are intended for general circulation and do not have regard to the specific investment objectives, financial situation and particular needs of any person. Accordingly, no warranty whatsoever is given and no liability whatsoever is accepted for any loss arising whether directly or indirectly as a result of any person acting based on this information. You should seek advice from a financial adviser regarding the suitability of any investment product(s) mentioned herein, taking into account your specific investment objectives, financial situation or particular needs, before making a commitment to invest in such products. Opinions expressed in these commentaries are subject to change without notice. Investments are subject to investment risks including the possible loss of the principal amount invested. The value of units in any fund and the income from them may fall as well as rise. Past performance figures as well as any projection or forecast used in these commentaries are not necessarily indicative of future or likely performance. Phillip Securities Pte Ltd (PSPL), its directors, connected persons or employees may from time to time have an interest in the financial instruments mentioned in these commentaries. The information contained in these commentaries has been obtained from public sources which PSPL has no reason to believe are unreliable and any analysis, forecasts, projections, expectations and opinions (collectively the “Research”) contained in these commentaries are based on such information and are expressions of belief only. PSPL has not verified this information and no representation or warranty, express or implied, is made that such information or Research is accurate, complete or verified or should be relied upon as such. Any such information or Research contained in these commentaries are subject to change, and PSPL shall not have any responsibility to maintain the information or Research made available or to supply any corrections, updates or releases in connection therewith. In no event will PSPL be liable for any special, indirect, incidental or consequential damages which may be incurred from the use of the information or Research made available, even if it has been advised of the possibility of such damages. The companies and their employees mentioned in these commentaries cannot be held liable for any errors, inaccuracies and/or omissions howsoever caused. Any opinion or advice herein is made on a general basis and is subject to change without notice. The information provided in these commentaries may contain optimistic statements regarding future events or future financial performance of countries, markets or companies. You must make your own financial assessment of the relevance, accuracy and adequacy of the information provided in these commentaries. Views and any strategies described in these commentaries may not be suitable for all investors. Opinions expressed herein may differ from the opinions expressed by other units of PSPL or its connected persons and associates. Any reference to or discussion of investment products or commodities in these commentaries is purely for illustrative purposes only and must not be construed as a recommendation, an offer or solicitation for the subscription, purchase or sale of the investment products or commodities mentioned.

    Hyphens Pharma International: Navigating Challenges with Strategic Focus

    Published on Mar 17, 2026 23 

    Company Overview Hyphens Pharma International is a pharmaceutical company operating across ASEAN markets with a diversified portfolio spanning specialty pharmaceuticals, proprietary brands, and medical hypermart operations. The company has been expanding its reach across Southeast Asia whilst making strategic inroads into European markets. Financial Performance and Strategic Refresh Hyphens Pharma delivered FY25 results broadly in line with expectations, with revenue and adjusted profit after tax and minority interests achieving 99% and 97% of forecasts respectively. The second half of FY25 demonstrated resilience, with adjusted PATMI rebounding 27% year-on-year to S$5.94 million, driven by the discontinuation of low-margin products and enhanced cost controls. However, the overall financial picture was mixed. Revenue declined 8% year-on-year to S$97.8 million in 2H25, primarily due to a 23% drop in Vietnamese operations. The company faced multiple headwinds in Vietnam, including elevated Sterimar, a natural, drug-free seawater nasal spray, inventory levels, deprioritisation of contrast media products, currency weakness, and strategic product discontinuations. Operational Challenges and Strategic Positives The company encountered significant operational hurdles, particularly in Vietnam, which necessitated a strategic refresh. We believe the company faced challenges in passing through higher-priced Euro specialty products to customers, prompting a realignment towards better-margin products. It allowed gross profit margins to improve substantially, jumping 5.7 percentage points year-on-year to 41.9% in 2H25, demonstrating the effectiveness of the margin enhancement strategy. The positive momentum was partially offset by increased provisions totalling several million dollars, including inventory write-offs of S$1 million, impairment of receivables worth S$0.6 million, and foreign exchange translation losses of S$0.8 million, all largely related to Vietnamese operations. Growth Prospects and Valuation Phillip Securities Research maintains a BUY recommendation with a target price of S$0.40, raising FY26 PATMI estimates by 10% to S$12.2 million based on improved gross margin projections. The company achieved a significant milestone in January with an out-licensing agreement for Cerapro MED, an atopic dermatitis treatment, across six European countries. Additionally, Winlevi anti-acne products are gaining traction in Singapore and Malaysia. Trading at an attractive 8x price-to-earnings ratio with net cash of S$26.8 million representing 27% of market capitalisation, the company appears well-positioned for recovery as Vietnamese operations stabilises and growth drivers including medical aesthetics and e-pharmacy initiatives gain momentum. Frequently Asked Questions Q: What was Hyphens Pharma's financial performance in FY25? A: FY25 revenue and adjusted PATMI were within expectations at 99% and 97% of forecasts respectively. 2H25 adjusted PATMI rebounded 27% year-on-year to S$5.94 million, though headline earnings declined due to FX translation losses and extraordinary provisions. Q: Why did revenue decline in 2H25? A: Revenue declined 8% year-on-year to S$97.8 million in 2H25, primarily driven by a 23% drop in Vietnamese operations due to elevated inventory, currency weakness, and strategic product discontinuations. Q: What challenges did the company face in Vietnam? A: Vietnam operations encountered elevated Sterimar inventory, deprioritisation of contrast media, weak currency conditions, discontinuation of several products, and difficulties in passing through higher-priced Euro specialty products to customers. Q: How did gross margins perform? A: Gross profit margins improved significantly, jumping 5.7 percentage points year-on-year to 41.9% in 2H25, helping gross profit grow despite declining revenue through discontinuation of low-margin products like Physiolac infant formula. Q: What is Phillip Securities Research's recommendation? A: Phillip Securities Research maintains a BUY recommendation with a target price of S$0.40, raising FY26 PATMI estimates by 10% to S$12.2 million based on higher gross margin estimates. Q: What are the key growth drivers for 2026? A: Expected growth drivers for 2026 include Winlevi anti-acne products, medical aesthetics, and Wellaway e-pharmacy operations, alongside the strategic refresh of Vietnam's product portfolio. Q: What significant milestone did the company achieve? A: In January, Hyphens reached a milestone with an out-licensing agreement for Cerapro MED, an atopic dermatitis treatment, into six European countries, marking successful expansion into European markets. Q: What is the company's current valuation and financial position? A: Hyphens trades at an attractive 8x price-to-earnings ratio with net cash of S$26.8 million, representing 27% of its market capitalisation, providing a strong financial foundation for future growth.

    IMPORTANT INFORMATION

    This material is provided by Phillip Capital Management (S) Ltd (“PCM”) for general information only and does not constitute a recommendation, an offer to sell, or a solicitation of any offer to invest in any of the exchange-traded fund (“ETF”) or the unit trust (“Products”) mentioned herein. It does not have any regard to your specific investment objectives, financial situation and any of your particular needs. You should read the Prospectus and the accompanying Product Highlights Sheet (“PHS”) for key features, key risks and other important information of the Products and obtain advice from a financial adviser (“FA“) pursuant to a separate engagement before making a commitment to invest in the Products. In the event that you choose not to obtain advice from a FA, you should assess whether the Products are suitable for you before proceeding to invest. A copy of the Prospectus and PHS are available from PCM, any of its Participating Dealers (“PDs“) for the ETF, or any of its authorised distributors for the unit trust managed by PCM.  

    An ETF is not like a typical unit trust as the units of the ETF (the “Units“) are to be listed and traded like any share on the Singapore Exchange Securities Trading Limited (“SGX-ST”). Listing on the SGX-ST does not guarantee a liquid market for the Units which may be traded at prices above or below its NAV or may be suspended or delisted. Investors may buy or sell the Units on SGX-ST when it is listed. Investors cannot create or redeem Units directly with PCM and have no rights to request PCM to redeem or purchase their Units. Creation and redemption of Units are through PDs if investors are clients of the PDs, who have no obligation to agree to create or redeem Units on behalf of any investor and may impose terms and conditions in connection with such creation or redemption orders. Please refer to the Prospectus of the ETF for more details.  

    Investments are subject to investment risks including the possible loss of the principal amount invested. The purchase of a unit in a fund is not the same as placing your money on deposit with a bank or deposit-taking company. There is no guarantee as to the amount of capital invested or return received. The value of the units and the income accruing to the units may fall or rise. Past performance is not necessarily indicative of the future or likely performance of the Products. There can be no assurance that investment objectives will be achieved.  

    Where applicable, fund(s) may invest in financial derivatives and/or participate in securities lending and repurchase transactions for the purpose of hedging and/or efficient portfolio management, subject to the relevant regulatory requirements. PCM reserves the discretion to determine if currency exposure should be hedged actively, passively or not at all, in the best interest of the Products.  

    The regular dividend distributions, out of either income and/or capital, are not guaranteed and subject to PCM’s discretion. Past payout yields and payments do not represent future payout yields and payments. Such dividend distributions will reduce the available capital for reinvestment and may result in an immediate decrease in the net asset value (“NAV”) of the Products. Please refer to <www.phillipfunds.com> for more information in relation to the dividend distributions.  

    The information provided herein may be obtained or compiled from public and/or third party sources that PCM has no reason to believe are unreliable. Any opinion or view herein is an expression of belief of the individual author or the indicated source (as applicable) only. PCM makes no representation or warranty that such information is accurate, complete, verified or should be relied upon as such. The information does not constitute, and should not be used as a substitute for tax, legal or investment advice.  

    The information herein are not for any person in any jurisdiction or country where such distribution or availability for use would contravene any applicable law or regulation or would subject PCM to any registration or licensing requirement in such jurisdiction or country. The Products is not offered to U.S. Persons. PhillipCapital Group of Companies, including PCM, their affiliates and/or their officers, directors and/or employees may own or have positions in the Products. Any member of the PhillipCapital Group of Companies may have acted upon or used the information, analyses and opinions herein before they have been published. 

    This advertisement has not been reviewed by the Monetary Authority of Singapore.  

     

    Phillip Capital Management (S) Ltd (Co. Reg. No. 199905233W)  
    250 North Bridge Road #06-00, Raffles City Tower ,Singapore 179101 
    Tel: (65) 6230 8133 Fax: (65) 65383066 www.phillipfunds.com